Cargando…

Circulating immune checkpoints predict heart failure outcomes

AIMS: There are limited data examining the role of immune checkpoint (IC) ligands in the pathophysiology of heart failure (HF). Therefore, we explore this in three HF animal models and in three different human cohorts (healthy, stable, and worsening HF). METHODS AND RESULTS: Transcriptomic analyses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Screever, Elles M., Yousif, Laura I.E., Moslehi, Javid J., Salem, Joe‐Elie, Voors, Adriaan A., Silljé, Herman H.W., de Boer, Rudolf A., Meijers, Wouter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375122/ https://www.ncbi.nlm.nih.gov/pubmed/37186066 http://dx.doi.org/10.1002/ehf2.14304

Ejemplares similares

A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
por: Piek, Arnold, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
por: Yousif, Laura I., et al.
Publicado: (2023)

Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart Failure
por: van den Berg, Pieter F., et al.
Publicado: (2023)

Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update
por: Suthahar, Navin, et al.
Publicado: (2018)

From Inflammation to Fibrosis—Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities
por: Suthahar, Navin, et al.
Publicado: (2017)

Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production
por: Du, Weijie, et al.
Publicado: (2018)

Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure
por: Vegter, Eline L., et al.
Publicado: (2017)

Evaluation of renal cancer progression in a mouse model of heart failure
por: Shi, Canxia, et al.
Publicado: (2021)

Clonal haematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers
por: Shi, Canxia, et al.
Publicado: (2022)

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
por: Yin, Meimei, et al.
Publicado: (2011)

The role of immune checkpoints in cardiovascular disease
por: Yousif, Laura I., et al.
Publicado: (2022)

Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure
por: Screever, Elles M., et al.
Publicado: (2023)

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction
por: Gehlken, Carolin, et al.
Publicado: (2021)

Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance
por: Pozder, Carolin, et al.
Publicado: (2023)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Kidney Function in Patients With Neuromuscular Disease: Creatinine Versus Cystatin C
por: Screever, Elles M., et al.
Publicado: (2021)

Multifactorial Diseases of the Heart, Kidneys, Lungs, and Liver and Incident Cancer: Epidemiology and Shared Mechanisms
por: Shi, Canxia, et al.
Publicado: (2023)

The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction
por: Withaar, Coenraad, et al.
Publicado: (2020)

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)

Comorbidities complicating heart failure: changes over the last 15 years
por: Screever, Elles M., et al.
Publicado: (2022)

Common risk factors for heart failure and cancer
por: Meijers, Wouter C, et al.
Publicado: (2019)

Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease
por: Aboumsallem, Joseph Pierre, et al.
Publicado: (2020)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis
por: Meijers, Wouter C., et al.
Publicado: (2014)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
por: Aras, Mandar A., et al.
Publicado: (2020)

Circulating plasma angiotensin-converting enzyme 2 concentration is elevated in patients with kidney disease and diabetes
por: Sama, Iziah E, et al.
Publicado: (2020)

The fibrosis-cell death axis in heart failure
por: Piek, A., et al.
Publicado: (2016)

Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin
por: Ruifrok, Willem-Peter T., et al.
Publicado: (2010)

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction
por: Yurista, Salva R., et al.
Publicado: (2020)

Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations
por: Vegter, Eline L., et al.
Publicado: (2017)

Heart Failure and Breast Cancer Therapies: Moving Towards Personalized Risk Assessment
por: Francis, Sanjeev A., et al.
Publicado: (2014)

Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure
por: Yurista, Salva R., et al.
Publicado: (2020)

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
por: Hilmi, Marc, et al.
Publicado: (2020)

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

Regulation of the (pro)renin–renin receptor in cardiac remodelling
por: Mahmud, Hasan, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_47s8h2i9dc7gnfa5ab7gcu1fpl